Autonomic dysfunction in progressive supranuclear palsy.
Autonomic dysfunction
Orthostatic hypotension
Photophobia
Progressive supranuclear palsy
Urinary incontinence
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
30
06
2022
accepted:
17
08
2022
revised:
16
08
2022
pubmed:
31
8
2022
medline:
7
1
2023
entrez:
30
8
2022
Statut:
ppublish
Résumé
The degree of involvement of the autonomic nervous system in progressive supranuclear palsy (PSP) has been investigated in several studies, often providing conflicting results. There is a need for a better characterization of autonomic dysfunction in PSP, to enhance our understanding of this highly disabling neurodegenerative disease including patients' needs and possibly be of value for clinicians in the differential diagnosis among Parkinsonian syndromes. We applied a systematic methodology to review existing literature on Pubmed regarding autonomic nervous system involvement in PSP. PSP reported quite frequently symptoms suggestive of autonomic dysfunction in all domains. Cardiovascular autonomic testing showed in some cases a certain degree of impairment (never severe). There was some evidence suggesting bladder dysfunction particularly in the storage phase. Dysphagia and constipation were the most common gastrointestinal symptoms. Instrumental tests seemed to confirm sudomotor and pupillomotor disturbances. PSP patients frequently reported visceral symptoms, however objective testing showed that not always these reflected actual autonomic impairment. Further studies are needed to better delineate autonomic profile and its prognostic role in PSP.
Sections du résumé
BACKGROUND
BACKGROUND
The degree of involvement of the autonomic nervous system in progressive supranuclear palsy (PSP) has been investigated in several studies, often providing conflicting results. There is a need for a better characterization of autonomic dysfunction in PSP, to enhance our understanding of this highly disabling neurodegenerative disease including patients' needs and possibly be of value for clinicians in the differential diagnosis among Parkinsonian syndromes.
METHODS
METHODS
We applied a systematic methodology to review existing literature on Pubmed regarding autonomic nervous system involvement in PSP.
RESULTS
RESULTS
PSP reported quite frequently symptoms suggestive of autonomic dysfunction in all domains. Cardiovascular autonomic testing showed in some cases a certain degree of impairment (never severe). There was some evidence suggesting bladder dysfunction particularly in the storage phase. Dysphagia and constipation were the most common gastrointestinal symptoms. Instrumental tests seemed to confirm sudomotor and pupillomotor disturbances.
CONCLUSIONS
CONCLUSIONS
PSP patients frequently reported visceral symptoms, however objective testing showed that not always these reflected actual autonomic impairment. Further studies are needed to better delineate autonomic profile and its prognostic role in PSP.
Identifiants
pubmed: 36042018
doi: 10.1007/s00415-022-11347-w
pii: 10.1007/s00415-022-11347-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-129Informations de copyright
© 2022. The Author(s).
Références
Kovacs GG (2017) Tauopathies. In: Kovacs GG, Alafuzoff I (eds) Handbook of clinical neurology. Elsevier, pp 355–368
Williams DR, De Silva R, Paviour DC et al (2005) Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 128:1247–1258. https://doi.org/10.1093/brain/awh488
doi: 10.1093/brain/awh488
Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987
doi: 10.1002/mds.26987
Freeman R, Wieling W, Axelrod FB et al (2011) Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21:69–72. https://doi.org/10.1007/s10286-011-0119-5
doi: 10.1007/s10286-011-0119-5
Mathias CJ (2003) Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg Psychiatry 74:iii31–iii41. https://doi.org/10.1136/jnnp.74.suppl_3.iii42
doi: 10.1136/jnnp.74.suppl_3.iii42
Baschieri F, Sambati L, Guaraldi P et al (2021) Neurogenic orthostatic hypotension in early stage Parkinson’s disease: New insights from the first 105 patients of the BoProPark study. Parkinsonism Relat Disord 93:12–18. https://doi.org/10.1016/j.parkreldis.2021.11.002
doi: 10.1016/j.parkreldis.2021.11.002
Radicati FG, Martinez Martin P, Fossati C et al (2017) Non motor symptoms in progressive supranuclear palsy: prevalence and severity. npj Park Dis 3:1–6. https://doi.org/10.1038/s41531-017-0037-x
doi: 10.1038/s41531-017-0037-x
Nojszewska M, Potulska-Chromik A, Jamrozik Z et al (2019) Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study. Neurol Neurochir Pol 53:26–33. https://doi.org/10.5603/PJNNS.a2019.0005
doi: 10.5603/PJNNS.a2019.0005
Ou R, Song W, Wei Q et al (2016) Characteristics of nonmotor symptoms in progressive supranuclear palsy. Parkinsons Dis. https://doi.org/10.1155/2016/9730319
doi: 10.1155/2016/9730319
Chaithra SP, Prasad S, Holla VV et al (2020) The non-motor symptom profile of progressive supranuclear palsy. J Mov Disord 13:118–126. https://doi.org/10.14802/jmd.19066
doi: 10.14802/jmd.19066
Colosimo C, Morgante L, Antonini A et al (2010) Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 257:5–14. https://doi.org/10.1007/s00415-009-5255-7
doi: 10.1007/s00415-009-5255-7
Berganzo K, Tijero B, Somme JH et al (2012) SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy. Park Relat Disord 18:45–48. https://doi.org/10.1016/j.parkreldis.2011.08.018
doi: 10.1016/j.parkreldis.2011.08.018
Bae H-J, Cheon S-M, Kim JW (2009) Autonomic dysfunctions in parkinsonian disorders. J Mov Disord 2:72–77. https://doi.org/10.14802/jmd.09019
doi: 10.14802/jmd.09019
Schmidt C, Herting B, Prieur S et al (2008) Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord 23:2083–2089. https://doi.org/10.1002/mds.22289
doi: 10.1002/mds.22289
Dubbioso R, Provitera V, Vitale F et al (2021) Cutaneous sensory and autonomic denervation in progressive supranuclear palsy. Neuropathol Appl Neurobiol 47:653–663. https://doi.org/10.1111/nan.12692
doi: 10.1111/nan.12692
Wenning GK, Scherfler C, Granata R et al (1999) Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 67:620–623. https://doi.org/10.1136/jnnp.67.5.620
doi: 10.1136/jnnp.67.5.620
Liu P, Chen Y, Wang B et al (2022) Cardiovascular autonomic dysfunction is associated with executive dysfunction and poorer quality of life in progressive supranuclear palsy-Richardson’s syndrome. J Clin Neurosci 96:147–153. https://doi.org/10.1016/j.jocn.2021.11.003
doi: 10.1016/j.jocn.2021.11.003
Kimber J, Mathias CJ, Lees AJ et al (2000) Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain 123:1422–1430
doi: 10.1093/brain/123.7.1422
Kikkawa Y, Asahina M, Suzuki A, Hattori T (2003) Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson’s disease. Park Relat Disord 10:101–106. https://doi.org/10.1016/S1353-8020(03)00109-3
doi: 10.1016/S1353-8020(03)00109-3
Schmidt C, Herting B, Prieur S et al (2009) Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm 116:875–880. https://doi.org/10.1007/s00702-009-0239-4
doi: 10.1007/s00702-009-0239-4
Schmidt C, Berg D, Herting B et al (2009) Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 24:2136–2142. https://doi.org/10.1002/mds.22767
doi: 10.1002/mds.22767
Reimann M, Schmidt C, Herting B et al (2010) Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 117:69–76. https://doi.org/10.1007/s00702-009-0313-y
doi: 10.1007/s00702-009-0313-y
Van Gerpen JA, Al-Shaikh RH, Tipton PW et al (2019) Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology 93:E1339–E1347. https://doi.org/10.1212/WNL.0000000000008197
doi: 10.1212/WNL.0000000000008197
Oliveira MCB, Ling H, Lees AJ et al (2019) Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 90:555–561. https://doi.org/10.1136/jnnp-2018-319374
doi: 10.1136/jnnp-2018-319374
Litvan I, Campbell G, Mangone CA et al (1997) Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain 120:65–74. https://doi.org/10.1093/brain/120.1.65
doi: 10.1093/brain/120.1.65
Respondek G, Stamelou M, Kurz C et al (2014) The Phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766. https://doi.org/10.1002/mds.26054
doi: 10.1002/mds.26054
Respondek G, Kurz C, Arzberger T et al (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 32:995–1005. https://doi.org/10.1002/mds.27034
doi: 10.1002/mds.27034
Koga S, Aoki N, Uitti RJ et al (2015) When DLB, PD, and PSP masquerade as MSA. Neurology 85:404–412. https://doi.org/10.1212/WNL.0000000000001807
doi: 10.1212/WNL.0000000000001807
Miki Y, Foti SC, Asi YT et al (2019) Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. Brain 142:2813–2827. https://doi.org/10.1093/brain/awz189
doi: 10.1093/brain/awz189
Gibbons CH, Schmidt P, Biaggioni I et al (2017) The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 264:1567–1582. https://doi.org/10.1007/s00415-016-8375-x
doi: 10.1007/s00415-016-8375-x
Norcliffe-Kaufmann L, Kaufmann H, Palma JA et al (2018) Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol 83:522–531. https://doi.org/10.1002/ana.25170
doi: 10.1002/ana.25170
Guaraldi P, Baschieri F, Barletta G et al (2020) Validation of the new index of baroreflex function to identify neurogenic orthostatic hypotension. Auton Neurosci Basic Clin 229:102744. https://doi.org/10.1016/j.autneu.2020.102744
doi: 10.1016/j.autneu.2020.102744
Fanciulli A, Jordan J, Biaggioni I et al (2018) Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). Clin Auton Res 28:355–362. https://doi.org/10.1007/s10286-018-0529-8
doi: 10.1007/s10286-018-0529-8
Ghika J, Bogousslavsky J (1997) Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol 54:1104–1108
doi: 10.1001/archneur.1997.00550210038010
Fabbrini G, Vanacore N, Bonifati V et al (1998) Presymptomatic hypertension in progressive supranuclear palsy. Arch Neurol 55:1153–1154. https://doi.org/10.1001/archneur.55.8.1153
doi: 10.1001/archneur.55.8.1153
Colosimo C, Osaki Y, Vanacore N, Less AJ (2003) Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study. Mov Disord 18:694–697. https://doi.org/10.1002/mds.10392
doi: 10.1002/mds.10392
Sibon I, Macia F, Vital A et al (2004) Hypertension and progressive supranuclear palsy: is everything so clear? Mov Disord 19:1259–1261
doi: 10.1002/mds.20275
Rabadia SV, Litvan I, Juncos J et al (2019) Hypertension and progressive supranuclear palsy. Park Relat Disord 66:166–170. https://doi.org/10.1016/j.parkreldis.2019.07.036
doi: 10.1016/j.parkreldis.2019.07.036
van Dijk JG, Haan J, Koenderink M, Roos RA (1991) Autonomic nervous function in progressive supranuclear palsy. Arch Neurol 48:1083–1084. https://doi.org/10.1001/archneur.1991.00530220105028
doi: 10.1001/archneur.1991.00530220105028
Sandroni P, Ahlskog JE, Fealey RD, Low PA (1991) Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res 1:147–155. https://doi.org/10.1007/BF01826212
doi: 10.1007/BF01826212
Gutrecht JA (1992) Autonomic cardiovascular reflexes in progressive supranuclear palsy. J Auton Nerv Syst 39:29–35. https://doi.org/10.1016/0165-1838(92)90248-F
doi: 10.1016/0165-1838(92)90248-F
Friedrich C, Rüdiger H, Schmidt C et al (2008) Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 115:1527–1536. https://doi.org/10.1007/s00702-008-0127-3
doi: 10.1007/s00702-008-0127-3
Friedrich C, Rüdiger H, Schmidt C et al (2010) Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 25:315–324. https://doi.org/10.1002/mds.22844
doi: 10.1002/mds.22844
Brefel-Courbon C, Thalamas C, Rascol O et al (2000) Lack of autonomic nervous dysfunction in progressive supranuclear palsy, a study of blood pressure variability. Clin Aut Res 10:309–312
doi: 10.1007/BF02281114
Holmberg B, Kallio M, Johnels B, Elam M (2001) Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes. Mov Disord 16:217–225. https://doi.org/10.1002/mds.1062
doi: 10.1002/mds.1062
Deguchi K, Sasaki I, Tsukaguchi M et al (2002) Abnormalities of rate-corrected QT intervals in Parkinson’s disease—a comparison with multiple system atrophy and progressive supranuclear palsy. J Neurol Sci 199:31–37. https://doi.org/10.1016/S0022-510X(02)00079-5
doi: 10.1016/S0022-510X(02)00079-5
Yoshita M (1998) Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta- iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60–67. https://doi.org/10.1016/S0022-510X(97)00278-5
doi: 10.1016/S0022-510X(97)00278-5
Nagayama H, Hamamoto M, Ueda M et al (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 76:249–251. https://doi.org/10.1136/jnnp.2004.037028
doi: 10.1136/jnnp.2004.037028
Tateno F, Sakakibara R, Kishi M et al (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Park Relat Disord 17:395–397. https://doi.org/10.1016/j.parkreldis.2011.02.001
doi: 10.1016/j.parkreldis.2011.02.001
Kurata T, Kametaka S, Ohta Y et al (2011) PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage. Intern Med 50:2775–2781. https://doi.org/10.2169/internalmedicine.50.5954
doi: 10.2169/internalmedicine.50.5954
Schubert E, Dogan S, Dillmann U et al (2019) MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration. Park Relat Disord 66:247–248. https://doi.org/10.1016/j.parkreldis.2019.07.003
doi: 10.1016/j.parkreldis.2019.07.003
Kamada T, Miura S, Kida H et al (2019) MIBG myocardial scintigraphy in progressive supranuclear palsy. J Neurol Sci 396:3–7. https://doi.org/10.1016/j.jns.2018.10.019
doi: 10.1016/j.jns.2018.10.019
Sakakibara R, Hattori T, Tojo M et al (1993) Micturitional disturbance in progressive supranuclear palsy. J Auton Nerv Syst 45:101–106. https://doi.org/10.1016/0165-1838(93)90122-B
doi: 10.1016/0165-1838(93)90122-B
Yamamoto T, Tateno F, Sakakibara R et al (2016) Urinary dysfunction in progressive supranuclear palsy compared with other parkinsonian disorders. PLoS ONE 11:1–12. https://doi.org/10.1371/journal.pone.0149278
doi: 10.1371/journal.pone.0149278
Kim KJ, Jeong SJ, Kim JM (2018) Neurogenic bladder in progressive supranuclear palsy: a comparison with Parkinson’s disease and multiple system atrophy. Neurourol Urodyn 37:1724–1730. https://doi.org/10.1002/nau.23496
doi: 10.1002/nau.23496
Donker-Kaat L, Boon AJW, Kamphorst W et al (2007) Frontal presentation in progressive supranuclear palsy. Neurology 69:723–729. https://doi.org/10.1212/01.wnl.0000267643.24870.26
doi: 10.1212/01.wnl.0000267643.24870.26
Lee YH, Lee JE, Ryu DW et al (2018) Urinary dysfunctions and post-void residual urine in typical and atypical Parkinson diseases. J Parkinsons Dis 8:145–152. https://doi.org/10.3233/JPD-171254
doi: 10.3233/JPD-171254
Tateno F, Sakakibara R, Kishi M et al (2011) Progressive supranuclear palsy presenting with urinary retention and sleep apnea. Clin Auton Res 21:173–175. https://doi.org/10.1007/s10286-010-0100-8
doi: 10.1007/s10286-010-0100-8
Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71:670–676. https://doi.org/10.1212/01.wnl.0000324625.00404.15
doi: 10.1212/01.wnl.0000324625.00404.15
Glasmacher SA, Leigh PN, Saha RA (2017) Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 88:402–411. https://doi.org/10.1136/jnnp-2016-314956
doi: 10.1136/jnnp-2016-314956
Clark HM, Stierwalt JAG, Tosakulwong N et al (2020) Dysphagia in progressive supranuclear palsy. Dysphagia 35:667–676. https://doi.org/10.1007/s00455-019-10073-2
doi: 10.1007/s00455-019-10073-2
Litvan I, Sastry N, Sonies BC (1997) Characterizing swallowing abnormalities in progressive supranuclear palsy. Neurology. https://doi.org/10.1212/WNL.48.6.1654
doi: 10.1212/WNL.48.6.1654
Johnston BT, Castell JA, Stumacher S et al (1997) Comparison of swallowing function in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 12:322–327. https://doi.org/10.1002/mds.870120310
doi: 10.1002/mds.870120310
Alfonsi E, Versino M, Merlo IM et al (2007) Electrophysiologic patterns of oral-pharyngeal swallowing in parkinsonian syndromes. Neurology 68:583–589. https://doi.org/10.1212/01.wnl.0000254478.46278.67
doi: 10.1212/01.wnl.0000254478.46278.67
Warnecke T, Oelenberg S, Teismann I et al (2010) Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord 25:1239–1245. https://doi.org/10.1002/mds.23060
doi: 10.1002/mds.23060
Clark HM, Tosakulwong N, Weigand SD et al (2021) Gray and white matter correlates of dysphagia in progressive supranuclear palsy. Mov Disord 36:2669–2675. https://doi.org/10.1002/mds.28731
doi: 10.1002/mds.28731
Claus I, Suttrup J, Muhle P et al (2018) Subtle esophageal motility alterations in parkinsonian syndromes: synucleinopathies vs. tauopathies. Mov Disord Clin Pract 5:406–412. https://doi.org/10.1002/mdc3.12616
doi: 10.1002/mdc3.12616
Leopold NA, Kagel MC (1997) Dysphagia in progressive supranuclear palsy: radiologic features. Dysphagia 12:140–143. https://doi.org/10.1007/PL00009528
doi: 10.1007/PL00009528
Ozawa T, Saji E, Yajima R et al (2011) Reduced bowel sounds in Parkinson’s disease and multiple system atrophy patients. Clin Auton Res 21:181–184. https://doi.org/10.1007/s10286-010-0102-6
doi: 10.1007/s10286-010-0102-6
Doi H, Sakakibara R, Tateno F, Aiba Y (2021) Colonic transit time in progressive supranuclear palsy and Parkinson’s disease. Neurol Clin Neurosci 9:91–94. https://doi.org/10.1111/ncn3.12473
doi: 10.1111/ncn3.12473
Lionnet A, Wade MA, Corbillé AG et al (2018) Characterisation of tau in the human and rodent enteric nervous system under physiological conditions and in tauopathy. Acta Neuropathol Commun 6:65. https://doi.org/10.1186/s40478-018-0568-3
doi: 10.1186/s40478-018-0568-3
Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 47:1–9. https://doi.org/10.1212/WNL.47.1.1
doi: 10.1212/WNL.47.1.1
Nath U, Ben-Shlomo Y, Thomson RG et al (2003) Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. https://doi.org/10.1212/01.WNL.0000052991.70149.68
doi: 10.1212/01.WNL.0000052991.70149.68
Cooper AD, Josephs KA (2009) Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. Park Relat Disord 15:59–61. https://doi.org/10.1016/j.parkreldis.2008.01.011
doi: 10.1016/j.parkreldis.2008.01.011
Schmidt C, Herting B, Prieur S et al (2007) Pupil diameter in darkness differentiates Progressive Supranuclear Palsy (PSP) from other extrapyramidal syndromes. Mov Disord 22:2123–2126. https://doi.org/10.1002/mds.21721
doi: 10.1002/mds.21721
Low PA (2008) Prevalence of orthostatic hypotension. Clin Auton Res 18:8–13. https://doi.org/10.1007/s10286-007-1001-3
doi: 10.1007/s10286-007-1001-3
Rüb U, Del Tredici K, Schultz C et al (2002) Progressive supranuclear palsy: Neuronal and glial cytoskeletal pathology in the higher order processing autonomic nuclei of the lower brainstem. Neuropathol Appl Neurobiol 28:12–22. https://doi.org/10.1046/j.0305-1846.2001.00374.x
doi: 10.1046/j.0305-1846.2001.00374.x
Iwasaki Y, Yoshida M, Hashizume Y et al (2007) Widespread spinal cord involvement in progressive supranuclear palsy. Neuropathology 27:331–340. https://doi.org/10.1111/j.1440-1789.2007.00787.x
doi: 10.1111/j.1440-1789.2007.00787.x
Vitaliani R, Scaravilli T, Egarter-Vigl E et al (2002) The pathology of the spinal cord in progressive supranuclear palsy. J Neuropathol Exp Neurol 61:268–274. https://doi.org/10.1093/jnen/61.3.268
doi: 10.1093/jnen/61.3.268
Wakabayashi K, Mori F, Tanji K et al (2010) Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain. Acta Neuropathol 120:1–12. https://doi.org/10.1007/s00401-010-0706-x
doi: 10.1007/s00401-010-0706-x
Painous C, Martí MJ, Simonet C et al (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Park Relat Disord 74:67–73. https://doi.org/10.1016/j.parkreldis.2020.03.003
doi: 10.1016/j.parkreldis.2020.03.003
Benarroch EE (2021) “Dysautonomia”: a plea for precision. Clin Auton Res 31:27–29. https://doi.org/10.1007/s10286-020-00749-3
doi: 10.1007/s10286-020-00749-3
Cheshire WP, Freeman R, Gibbons CH et al (2021) Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol 132:666–682. https://doi.org/10.1016/j.clinph.2020.11.024
doi: 10.1016/j.clinph.2020.11.024